CME Group Financials
This page shows CME Group (CME) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 19 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
CME’s capital-light cash engine turns higher activity into outsized profit and free cash flow with little reinvestment.
Across the recent periods, net income climbed from$3.23B to$4.07B , and free cash flow kept pace rather than lagging. With capex only$84M in FY2025, this looks like a throughput model where higher activity becomes cash instead of being tied up in reinvestment.
The balance sheet is large but self-offsetting: current assets of
Operating margin expanded from
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of CME Group's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
CME Group has an operating margin of 64.9%, meaning the company retains $65 of operating profit per $100 of revenue. This strong profitability earns a score of 99/100, reflecting efficient cost management and pricing power. This is up from 64.1% the prior year.
CME Group's revenue grew 6.4% year-over-year to $6.5B, a solid pace of expansion. This earns a growth score of 61/100.
CME Group has elevated debt relative to equity (D/E of 5.91), meaning the company relies heavily on borrowed funds. This high leverage results in a low score of 9/100, reflecting increased financial risk.
CME Group's current ratio of 1.03 is below the typical benchmark, resulting in a score of 20/100. This tight liquidity could limit financial flexibility if cash inflows slow.
CME Group converts 64.3% of revenue into free cash flow ($4.2B). This strong cash generation earns a score of 99/100.
CME Group earns a strong 14.2% return on equity (ROE), meaning it generates $14 of profit for every $100 of shareholders' equity. This efficient capital use earns a returns score of 76/100. This is up from 13.3% the prior year.
CME Group scores 0.49, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($86.6B) relative to total liabilities ($169.7B). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
CME Group passes 4 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 3 of 4 profitability signals pass, all 1 leverage/liquidity signals pass, neither operating efficiency signal passes.
For every $1 of reported earnings, CME Group generates $1.05 in operating cash flow ($4.3B OCF vs $4.1B net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.
CME Group earns $24.4 in operating income for every $1 of interest expense ($4.2B vs $173.4M). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.
Key Financial Metrics
Earnings & Revenue
CME Group generated $6.5B in revenue in fiscal year 2025. This represents an increase of 6.4% from the prior year.
CME Group's EBITDA was $4.3B in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 7.2% from the prior year.
CME Group reported $4.1B in net income in fiscal year 2025. This represents an increase of 15.5% from the prior year.
CME Group earned $11.16 per diluted share (EPS) in fiscal year 2025. This represents an increase of 15.4% from the prior year.
Cash & Balance Sheet
CME Group generated $4.2B in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 16.6% from the prior year.
CME Group held $4.4B in cash against $0 in long-term debt as of fiscal year 2025.
CME Group paid $5.00 per share in dividends in fiscal year 2025. This represents a decrease of 51.9% from the prior year.
Margins & Returns
CME Group's operating margin was 64.9% in fiscal year 2025, reflecting core business profitability. This is up 0.7 percentage points from the prior year.
CME Group's net profit margin was 62.5% in fiscal year 2025, showing the share of revenue converted to profit. This is up 4.9 percentage points from the prior year.
CME Group's ROE was 14.2% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 0.9 percentage points from the prior year.
Capital Allocation
CME Group invested $83.5M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 11.2% from the prior year.
CME Income Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.9B+14.0% | $1.6B+7.2% | $1.5B-9.1% | $1.7B+3.0% | $1.6B+7.7% | $1.5B-3.7% | $1.6B+3.4% | $1.5B |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| SG&A Expenses | $223.0M-7.5% | $241.1M+1.5% | $237.6M+7.2% | $221.6M+7.2% | $206.7M-6.4% | $220.8M+0.9% | $218.8M+6.9% | $204.7M |
| Operating Income | $1.3B+28.5% | $1.0B+4.8% | $972.6M-13.9% | $1.1B+1.9% | $1.1B+17.0% | $947.1M-7.5% | $1.0B+2.4% | $1.0B |
| Interest Expense | $43.6M-0.2% | $43.7M-0.7% | $44.0M0.0% | $44.0M+5.5% | $41.7M+2.5% | $40.7M+1.2% | $40.2M+0.2% | $40.1M |
| Income Tax | $356.6M-9.8% | $395.5M+47.0% | $269.0M-11.9% | $305.2M+5.8% | $288.6M+30.0% | $222.0M-15.9% | $264.1M-2.7% | $271.3M |
| Net Income | $1.2B-2.4% | $1.2B+30.3% | $908.0M-11.4% | $1.0B+7.2% | $956.2M+9.3% | $874.6M-4.2% | $912.8M+3.4% | $883.2M |
| EPS (Diluted) | $3.18 | N/A | $2.49-11.4% | $2.81+7.3% | $2.62 | N/A | $2.50+3.3% | $2.42 |
CME Balance Sheet
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $202.0B+1.8% | $198.4B+6.0% | $187.1B+4.0% | $179.9B+14.0% | $157.8B+14.8% | $137.4B-0.3% | $137.8B+11.7% | $123.4B |
| Current Assets | $169.0B+2.2% | $165.4B+8.2% | $152.8B+5.1% | $145.5B+17.8% | $123.4B+19.8% | $103.0B-0.1% | $103.1B+16.2% | $88.7B |
| Cash & Equivalents | $2.4B-45.9% | $4.4B+80.5% | $2.4B+23.5% | $2.0B+41.0% | $1.4B-51.4% | $2.9B+24.6% | $2.3B+29.7% | $1.8B |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | $935.5M+46.4% | $639.2M-0.6% | $642.9M-3.7% | $667.6M-13.3% | $770.2M+34.4% | $573.1M-8.9% | $629.4M+5.0% | $599.5M |
| Goodwill | $10.5B-0.1% | $10.5B0.0% | $10.5B-0.1% | $10.5B+0.2% | $10.5B+0.1% | $10.5B-0.3% | $10.5B+0.2% | $10.5B |
| Total Liabilities | $175.4B+3.3% | $169.7B+6.8% | $159.0B+4.5% | $152.2B+16.3% | $130.8B+17.9% | $111.0B+1.3% | $109.6B+14.5% | $95.7B |
| Current Liabilities | $166.0B+3.6% | $160.3B+7.2% | $149.6B+4.8% | $142.8B+17.6% | $121.4B+18.7% | $102.3B+1.5% | $100.8B+15.9% | $87.0B |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $26.6B-7.3% | $28.7B+1.9% | $28.2B+1.6% | $27.7B+2.6% | $27.0B+2.1% | $26.5B-6.1% | $28.2B+2.1% | $27.6B |
| Retained Earnings | $4.9B-24.1% | $6.4B+12.7% | $5.7B+8.6% | $5.3B+12.1% | $4.7B+11.9% | $4.2B-28.4% | $5.8B+9.2% | $5.4B |
CME Cash Flow Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $1.3B+11.1% | $1.1B+17.1% | $968.1M-8.5% | $1.1B-5.2% | $1.1B+9.7% | $1.0B+1.5% | $1.0B+29.1% | $776.9M |
| Capital Expenditures | $21.8M-32.9% | $32.5M+76.6% | $18.4M0.0% | $18.4M+29.6% | $14.2M-45.8% | $26.2M-12.1% | $29.8M+63.7% | $18.2M |
| Free Cash Flow | $1.2B+12.4% | $1.1B+16.0% | $949.7M-8.7% | $1.0B-5.7% | $1.1B+11.2% | $991.7M+1.9% | $973.2M+28.3% | $758.7M |
| Investing Cash Flow | -$23.0M-101.5% | $1.6B+8225.1% | -$19.1M-6.1% | -$18.0M-12.5% | -$16.0M+36.8% | -$25.3M+14.2% | -$29.5M-490.0% | -$5.0M |
| Financing Cash Flow | $2.1B-78.6% | $9.9B+54.7% | $6.4B-69.5% | $21.0B+9.3% | $19.2B+2052.2% | -$984.1M-107.4% | $13.3B+244.7% | -$9.2B |
| Dividends Paid | $2.7B+492.9% | $455.0M-0.1% | $455.3M0.0% | $455.3M-82.3% | $2.6B+513.0% | $418.8M+0.1% | $418.5M0.0% | $418.5M |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
CME Financial Ratios
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | 69.7%+7.8pp | 61.8%-1.4pp | 63.2%-3.5pp | 66.7%-0.7pp | 67.5%+5.4pp | 62.1%-2.5pp | 64.6%-0.7pp | 65.3% |
| Net Margin | 61.4%-10.4pp | 71.8%+12.7pp | 59.1%-1.5pp | 60.6%+2.4pp | 58.2%+0.9pp | 57.3%-0.3pp | 57.6%-0.0pp | 57.6% |
| Return on Equity | 4.3%+0.2pp | 4.1%+0.9pp | 3.2%-0.5pp | 3.7%+0.2pp | 3.5%+0.2pp | 3.3%+0.1pp | 3.2%+0.0pp | 3.2% |
| Return on Assets | 0.6%-0.0pp | 0.6%+0.1pp | 0.5%-0.1pp | 0.6%-0.0pp | 0.6%-0.0pp | 0.6%-0.0pp | 0.7%-0.1pp | 0.7% |
| Current Ratio | 1.02-0.0 | 1.03+0.0 | 1.020.0 | 1.020.0 | 1.020.0 | 1.01-0.0 | 1.020.0 | 1.02 |
| Debt-to-Equity | 6.59+0.7 | 5.91+0.3 | 5.64+0.2 | 5.49+0.6 | 4.84+0.6 | 4.19+0.3 | 3.88+0.4 | 3.46 |
| FCF Margin | 65.8%-1.0pp | 66.8%+5.0pp | 61.8%+0.3pp | 61.5%-5.7pp | 67.1%+2.1pp | 65.0%+3.6pp | 61.4%+11.9pp | 49.5% |
Similar Companies
Frequently Asked Questions
What is CME Group's annual revenue?
CME Group (CME) reported $6.5B in total revenue for fiscal year 2025. This represents a 6.4% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is CME Group's revenue growing?
CME Group (CME) revenue grew by 6.4% year-over-year, from $6.1B to $6.5B in fiscal year 2025.
Is CME Group profitable?
Yes, CME Group (CME) reported a net income of $4.1B in fiscal year 2025, with a net profit margin of 62.5%.
What is CME Group's EBITDA?
CME Group (CME) had EBITDA of $4.3B in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is CME Group's operating margin?
CME Group (CME) had an operating margin of 64.9% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is CME Group's net profit margin?
CME Group (CME) had a net profit margin of 62.5% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
Does CME Group pay dividends?
Yes, CME Group (CME) paid $5.00 per share in dividends during fiscal year 2025.
What is CME Group's return on equity (ROE)?
CME Group (CME) has a return on equity of 14.2% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is CME Group's free cash flow?
CME Group (CME) generated $4.2B in free cash flow during fiscal year 2025. This represents a 16.6% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is CME Group's operating cash flow?
CME Group (CME) generated $4.3B in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are CME Group's total assets?
CME Group (CME) had $198.4B in total assets as of fiscal year 2025, including both current and long-term assets.
What are CME Group's capital expenditures?
CME Group (CME) invested $83.5M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
What is CME Group's current ratio?
CME Group (CME) had a current ratio of 1.03 as of fiscal year 2025, which is considered adequate.
What is CME Group's debt-to-equity ratio?
CME Group (CME) had a debt-to-equity ratio of 5.91 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is CME Group's return on assets (ROA)?
CME Group (CME) had a return on assets of 2.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is CME Group's Altman Z-Score?
CME Group (CME) has an Altman Z-Score of 0.49, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is CME Group's Piotroski F-Score?
CME Group (CME) has a Piotroski F-Score of 4 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are CME Group's earnings high quality?
CME Group (CME) has an earnings quality ratio of 1.05x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can CME Group cover its interest payments?
CME Group (CME) has an interest coverage ratio of 24.4x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is CME Group?
CME Group (CME) scores 61 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.